TY - JOUR
T1 - Biological and molecular characterization of PNH-like lymphocytes emerging after Campath-1H therapy
AU - Fracchiolla, Nicola S.
AU - Barcellini, Wilma
AU - Bianchi, Paola
AU - Motta, Marina
AU - Fermo, Elisa
AU - Cortelezzi, Agostino
PY - 2001
Y1 - 2001
N2 - Campath-1H, an anti-CD52 monoclonal antibody, is therapeutically active in lymphoproliferative and autoimmune diseases. After Campath-1H therapy, lymphocytes with a paroxysmal nocturnal haemoglobinuria (PNH) phenotype have been reported to emerge. We characterized a PNH-like lymphocyte population emerging after Campath-1H therapy, in a patient with fludarabine refractory B-cell chronic lymphocytic leukaemia (B-CLL). We demonstrated a reduction in PIG-A mRNA levels compared with controls, and of all cytokines tested [interleukin (IL)-4, IL-13, IL-2, interferon(IFN)-γ, IL-6, IL-10, and tumour necrosis factor (TNF)-α], except transforming growth factor (TGF)-β. Given the inhibitory activity of TGF-β, its elevated levels may contribute to the selective pressure of Campath-1H, leading to the emergence of PNH-like lymphocytes.
AB - Campath-1H, an anti-CD52 monoclonal antibody, is therapeutically active in lymphoproliferative and autoimmune diseases. After Campath-1H therapy, lymphocytes with a paroxysmal nocturnal haemoglobinuria (PNH) phenotype have been reported to emerge. We characterized a PNH-like lymphocyte population emerging after Campath-1H therapy, in a patient with fludarabine refractory B-cell chronic lymphocytic leukaemia (B-CLL). We demonstrated a reduction in PIG-A mRNA levels compared with controls, and of all cytokines tested [interleukin (IL)-4, IL-13, IL-2, interferon(IFN)-γ, IL-6, IL-10, and tumour necrosis factor (TNF)-α], except transforming growth factor (TGF)-β. Given the inhibitory activity of TGF-β, its elevated levels may contribute to the selective pressure of Campath-1H, leading to the emergence of PNH-like lymphocytes.
KW - Campath-1H
KW - CLL
KW - Cytokines
KW - PIG-A
KW - PNH-like lymphocytes
UR - http://www.scopus.com/inward/record.url?scp=0035053076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035053076&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2141.2001.02677.x
DO - 10.1046/j.1365-2141.2001.02677.x
M3 - Article
C2 - 11298593
AN - SCOPUS:0035053076
VL - 112
SP - 969
EP - 971
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 4
ER -